Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE2 | O96020 | 1/20 | 0.44 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.44 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.44 |
| ▸ | CDK2 | P24941 | 1/20 | 0.44 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 3/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA7 | P43166 | 2/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.38 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.37 |
| ▸ | FDPS | P14324 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL644995 | 0.86 | PPARA (0.44) | ATMCTSSCTSKAPP | |
| SCHEMBL647288 | 0.85 | KLK5 (0.40) | CCNE2CCNA2CCNE1CDK2CCNA1 | |
| SCHEMBL4269459 | 0.81 | TRPA1 (0.41) | ATMCA2CA1CA7CA4 | |
| SCHEMBL4269455 | 0.79 | LATS1 (0.50) | CA2CA1CA9KDM4EALDH1A1 | |
| SCHEMBL550667 | 0.78 | METAP1 (0.46) | CA2CA1CA9KDM4EALDH1A1 | |
| SCHEMBL15156727 | 0.77 | KDM4E (0.42) | CA2CA1CA9KDM4EALDH1A1 | |
| SCHEMBL28650853 | 0.76 | HDAC1 (0.39) | CA2CA1CA9KDM4EALDH1A1 | |
| SCHEMBL16879880 | 0.76 | GAA (0.47) | CA2CA1CA9KDM4EALDH1A1 | |
| SCHEMBL20157340 | 0.75 | CCNE2 (0.42) | CCNE2CCNA2CCNE1CDK2CCNA1 | |
| SCHEMBL13257888 | 0.74 | ATM (0.50) | CCNE2CCNA2CCNE1CDK2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165319-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-28 | — | — | US | disclosed |
| US-8119631-B2 | Inhibitors of interleukin-1β converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-21 | — | — | US | disclosed |
| US-20110178069-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-21 | — | — | US | disclosed |
| US-7790713-B2 | Inhibitors of interleukin-1β converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-09-07 | — | — | US | disclosed |
| US-20080039449-A1 | Inhibitors of interleukin-1beta converting enzyme | BATCHELOR MARK J | 2008-02-14 | — | — | US | disclosed |
| US-20050143436-A1 | Inhibitors of interleukin-1beta converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED | 2005-06-30 | — | — | US | disclosed |
| US-20030225269-A1 | Inhibitors of interleukin-1beta converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED | 2003-12-04 | — | — | US | disclosed |
| US-6204261-B1 | Inhibitors of interleukin-1β Converting enzyme inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2001-03-20 | — | — | US | disclosed |
| EP-0869967-A2 | INHIBITORS OF INTERLEUKIN-1$g(b) CONVERTING ENZYME | Vertex Pharmaceuticals Incorporated (US) | 1998-10-14 | — | — | EP | disclosed |
| WO-1997022619-A2 | INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1997-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178069-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | IL1A, IFNAR1, IL1B | CCNE2 2629/4885CCNA2 2395/4885CCNE1 1473/4885 |
| US-20120165319-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | IL1A, IFNAR1, IL1B | CCNE2 2629/4885CCNA2 2395/4885CCNE1 1473/4885 |
| US-20080039449-A1 | Inhibitors of interleukin-1beta converting enzyme | IL1A, IL1B, IFNAR1 | CCNE2 2366/4885CCNA2 2037/4885CCNE1 1284/4885 |
| US-20050143436-A1 | Inhibitors of interleukin-1beta converting enzyme | IL1A, IL1B, IFNAR1 | CCNE2 2354/4885CCNA2 2052/4885CCNE1 1250/4885 |
| US-20030225269-A1 | Inhibitors of interleukin-1beta converting enzyme | IL1A, APAF1, IL1B | CCNE2 2505/4885CCNA2 2043/4885CCNE1 1467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.